Evidence map›Paper›PMID 32103758›Full record

ArticleBehavioral and brain functions : BBF2020

Naringin provides neuroprotection in CCL2-induced cognition impairment by attenuating neuronal apoptosis in the hippocampus.

Jiang-Yi Long, Jian-Min Chen, Yuan-Jun Liao, Yi-Jun Zhou, Bing-Yu Liang, Yan Zhou

Open access · goldAbstract read
In one paragraph

Article in Behavioral and brain functions : BBF, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Naringin Prevents Cognitive Dysfunction in Aging Rats by Inhibiting Toll-Like Receptor 4 (TLR4)/NF-Evidence-based complementary and alternative medicine : eCAM · 2023
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jiang-Yi LongDepartment of Pharmacology, Guangxi Medical University, Nanning, 53002, Guangxi, China.
Jian-Min ChenDepartment of Pharmacology, Guangxi Medical University, Nanning, 53002, Guangxi, China.
Yuan-Jun LiaoDepartment of Pharmacology, Guangxi Medical University, Nanning, 53002, Guangxi, China.
Yi-Jun ZhouDepartment of Pharmacology, Guangxi Medical University, Nanning, 53002, Guangxi, China.
Bing-Yu LiangGuangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Medical University, Nanning, 530021, Guang, China.
Yan ZhouDepartment of Pharmacology, Guangxi Medical University, Nanning, 53002, Guangxi, China. zhouyan@stu.gxmu.edu.cn.ORCID http://orcid.org/0000-0003-0757-4341
Guangxi Medical University · CN

Funding

National Foundation of Guangxi 2018JJA140536National Natural Foundation of China 81660213This work was supported by the National Natural Foundation of China 81360192
6 · The paper itself

Abstract

backgroundChemokine C-C motif ligand 2 (CCL2) is one of the most widely recognised proinflammatory chemokines in cognitive disorders. Currently, CCL2-targeting drugs are extremely limited. Thus, this study aimed to explore the neuroprotection afforded by naringin in CCL2-induced cognitive impairment in rats.

methodsBefore the CCL2 intra-hippocampal injection, rats were treated with naringin for 3 consecutive days via intraperitoneal injection. Two days post-surgery, the Morris water maze (MWM) and novel object recognition (NORT) tests were performed to detect spatial learning and memory and object cognition, respectively. Nissl staining and dUTP nick-end labelling (TUNEL) staining were performed to assess histopathological changes in the hippocampus. Commercial kits were used to measure the activity of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and the content of malondialdehyde (MDA). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to examine the relative mRNA expression of interleukin 1β, (IL-1β), interleukin 6 (IL-6), glutamate/aspartate transporter (GLAST), glutamate transporter-1 (GLT-1), phosphate-activated glutaminase (PAG), cysteine aspartic acid-specific protease 8 (caspase-8), cysteine aspartic acid-specific protease 3 (caspase-3), cell lymphoma/leukaemia-2 (Bcl-2), and Bcl-2 associated X protein (Bax).

resultsIn the MWM, the average escape latency and average swimming distance were significantly reduced and the crossing times were increased in the naringin-treated groups, compared with the CCL2 group. The NORT results revealed that, compared with the CCL2 rats, the discrimination index in the naringin-treated rats increased significantly. Nissl and TUNEL staining revealed that naringin protected the structure and survival of the neurons in the CA1 zone of the hippocampus. In the naringin-treated groups, the SOD and GSH-Px activities were increased, whereas the MDA levels were decreased. Furthermore, in the naringin-treated groups, the relative mRNA expression of IL-1β and IL-6 was significantly decreased; GLAST and GLT-1 mRNA expression levels were increased, whereas PAG was decreased. In the naringin-treated groups, the relative mRNA expression levels of caspase-8, caspase-3, and Bax were decreased, whereas that of Bcl-2 was increased.

conclusionCollectively, these data indicated that naringin alleviated the CCL2-induced cognitive impairment. The underlying mechanisms could be associated with the inhibition of neuroinflammation, oxidative stress, apoptosis, and the regulation of glutamate metabolism.

Indexed as

Chemokine CCL2AnimalsAntioxidantsApoptosisCell SurvivalCognitive DysfunctionCytokinesDiscrimination, PsychologicalEscape ReactionFlavanonesGene Expression RegulationHippocampusMaleMorris Water Maze TestNeuronsNeuroprotective AgentsAntioxidantsChemokine CCL2CytokinesFlavanonesnaringinNeuroprotective AgentsAnti-inflammationAntioxidantsApoptosisCognitive impairmentGlutamate metabolismNaringin

Identifiers

PMID32103758
PMCPMC7045422
OpenAlexW3011514705

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.